SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.07 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 16, 2018, the Board of Directors of Second Sight Medical Products, Inc. (the “Company” or “Second Sight”) appointed Stephen Okland, Commercial Vice President, U.S. and Canada, as the Company’s Chief Commercial Officer and increased his annual base salary from $267,800 to $282,800 and granted him options to purchase 50,000 shares of common stock under the Company’s 2011 Equity Incentive Plan. The options have an exercise price of $2.05 per share, which was the closing price of Company’s common stock as reported by Nasdaq on the date of grant, May 16, 2018. The options have a 10-year term and vest 25% on the one year anniversary of the grant date and 6.25% each calendar quarter thereafter until fully vested subject to continuous employment with the Company.
Item 5.07.Submission of Matters to a Vote of Security Holders
The 2018 Annual Meeting of Stockholders of Second Sight was held on May 16, 2018 in Los Angeles, California. Holders of 43,752,811 shares of common stock were represented at the meeting in person or by proxy, constituting a quorum. The following are the voting results on each matter submitted to the stockholders of Second Sight at the annual meeting. The proposals acted upon by the stockholders are described in detail in Second Sight's Proxy Statement which was filed with the Securities and Exchange Commission on April 13, 2018.
Proposal 1: The stockholders elected each of the five director nominees to the Board of Directors of the Company to serve until the 2019 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, as follows:
| Nominee | For | Against | Abstentions | Broker Non-Votes |
| Will McGuire | 23,377,603 | 136,247 | 46,491 | 20,192,470 |
| William J. Link | 22,970,884 | 187,604 | 401,853 | 20,192,470 |
| Gregg Williams | 23,029,563 | 155,646 | 375,132 | 20,192,470 |
| Aaron Mendelsohn | 23,274,641 | 153,723 | 131,977 | 20,192,470 |
| Matthew Pfeffer | 23,112,043 | 165,154 | 283,144 | 20,192,470 |
Proposal 2: The stockholders approved an amendment to the 2011 Equity Incentive Plan (“Plan”) to increase the maximum number of shares of common stock that may be issued under the Plan to 12 million shares, as follows:
| For | Against | Abstentions | Broker Non-Votes |
| 22,301,734 | 1,169,910 | 88,697 | 20,192,470 |
Proposal 3: The stockholders approved an amendment to Second Sight's 2015 Employee Stock Purchase Plan to increase the maximum stated number of shares of common stock which may be issued under the plan to 1,550,000 shares and increase annual evergreen amount to 500,000 shares, as follows:
| For | Against | Abstentions | Broker Non-Votes |
| 22,770,839 | 689,040 | 100,462 | 20,192,470 |
Proposal 4: The stockholders ratified the appointment of Gumbiner Savett Inc. as Second Sight’s independent registered public accounting firm for the year ending December 31, 2018, as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 42,802,247 | 730,545 | 220,019 | |
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.